-
Your selected country is
Japan
- Change country/language
-
抗体試薬
- フローサイトメトリー用試薬
-
ウェスタンブロッティング抗体試薬
- イムノアッセイ試薬
-
シングルセル試薬
- BD® AbSeq Assay | シングルセル試薬
- BD Rhapsody™ Accessory Kits | シングルセル試薬
- BD® Single-Cell Multiplexing Kit | シングルセル試薬
- BD Rhapsody™ Targeted mRNA Kits | シングルセル試薬
- BD Rhapsody™ Whole Transcriptome Analysis (WTA) Amplification Kit | シングルセル試薬
- BD® OMICS-Guard Sample Preservation Buffer
- BD Rhapsody™ ATAC-Seq Assays
- BD Rhapsody™ TCR/BCR Next Multiomic Assays
- BD® OMICS-One Immune Profiler Protein Panel
-
細胞機能評価のための試薬
-
顕微鏡・イメージング用試薬
-
細胞調製・分離試薬
-
- BD® AbSeq Assay | シングルセル試薬
- BD Rhapsody™ Accessory Kits | シングルセル試薬
- BD® Single-Cell Multiplexing Kit | シングルセル試薬
- BD Rhapsody™ Targeted mRNA Kits | シングルセル試薬
- BD Rhapsody™ Whole Transcriptome Analysis (WTA) Amplification Kit | シングルセル試薬
- BD® OMICS-Guard Sample Preservation Buffer
- BD Rhapsody™ ATAC-Seq Assays
- BD Rhapsody™ TCR/BCR Next Multiomic Assays
- BD® OMICS-One Immune Profiler Protein Panel
- Japan (Japanese)
- Change country/language
Old Browser
Looks like you're visiting us from {countryName}.
Would you like to stay on the current country site or be switched to your country?
Regulatory Statusの凡例
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Preparation and Storage
推奨アッセイ手順
BD® CompBeads can be used as surrogates to assess fluorescence spillover (compensation). When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.
Product Notices
- Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
- Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
- For U.S. patents that may apply, see bd.com/patents.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
- Since applications vary, each investigator should titrate the reagent to obtain optimal results.
- The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
- Human donor specific background has been observed in relation to the presence of anti-polyethylene glycol (PEG) antibodies, developed as a result of certain vaccines containing PEG, including some COVID-19 vaccines. We recommend use of BD Horizon Brilliant™ Stain Buffer in your experiments to help mitigate potential background. For more information visit https://www.bdbiosciences.com/en-us/support/product-notices.
- When using high concentrations of antibody, background binding of this dye to erythroid fragments produced by ammonium chloride-based lysis, such as with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899), has been observed when the antibody conjugate was present during the lysis procedure. This may cause nonspecific staining of target cells, such as leukocytes, which have bound the resulting erythroid fragments. This background can be mitigated by any of the following: titrating the antibody conjugate to a lower concentration, fixing samples with formaldehyde, or removing erythrocytes before staining (eg, gradient centrifugation or pre-lysis with wash). This background has not been observed when cells were lysed with BD FACS™ Lysing Solution (Cat. No. 349202) after staining.
- For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
- An isotype control should be used at the same concentration as the antibody of interest.
- Cy is a trademark of Global Life Sciences Solutions Germany GmbH or an affiliate doing business as Cytiva.
- Please observe the following precautions: We recommend that special precautions be taken (such as wrapping vials, tubes, or racks in aluminum foil) to protect exposure of conjugated reagents, including cells stained with those reagents, to any room illumination. Absorption of visible light can significantly affect the emission spectra and quantum yield of tandem fluorochrome conjugates.
関連製品
KS1/4 antigen (Ag), defined by the KS1/4 antibody (KS1/4), is expressed in many epithelial-derived carcinomas and normal epithelial cell surfaces. The cDNA encoding KS1/4 has been isolated and contains an open reading frame of 314 amino acids including a putative signal sequence. KS1/4 Ag migrates as three glycosylated polypeptides with molecular masses of 35, 40 and 42 kDa. The 40 and 42 kDa species are similar proteins and appear to differ only by their degree of N-linked glycosylation. The 35 kDa species results from proteolytic cleavages of the larger molecular weight proteins. KS1/4 was first described as a monoclonal antibody which recognized a lung adenocarcinoma associated antigen. In oncolytic drug targeting studies, KS1/4 suppressed the growth of human lung tumor xenografts in athymic nude mice. Subsequent studies showed that KS1/4 reacts with a variety of tumor tissues including colon, breast, ovarian, and pancreas. It also recognizes normal epithelium including colon, stomach, small intestine, liver, kidney, lung, pancreas, skin and ovary. These results suggest that KS1/4 Ag represents an epithelial cell/epithelial-derived carcinoma marker. KS1/4 recognizes a 40 - 42 kDa antigen expressed on the cell surfaces of a variety of epithelial tumors and normal epithelial cell types. KS1/4 also recognizes a 35 kDa proteolytic fragment. UCLA-P3 cells derived from a human adenocarcinoma of the lung were used as immunogen.
Development References (5)
-
Bumol TF, Marder P, DeHerdt SV, Borowitz MJ, Apelgren LD. Characterization of the human tumor and normal tissue reactivity of the KS1/4 monoclonal antibody. Hybridoma. 1988; 7(4):407-415. (Clone-specific: Flow cytometry, Immunohistochemistry). View Reference
-
Perez MS, Walker LE. Isolation and characterization of a cDNA encoding the KS1/4 epithelial carcinoma marker. J Immunol. 1989; 142(10):3662-3667. (Clone-specific: Immunoprecipitation). View Reference
-
Spearman ME, Goodwin RM, Apelgren LD, Bumol TF. Disposition of the monoclonal antibody-vinca alkaloid conjugate KS1/4-DAVLB (LY256787) and free 4-desacetylvinblastine in tumor-bearing nude mice. J Pharmacol Exp Ther. 1987; 241(2):695-703. (Biology). View Reference
-
Varki NM, Reisfeld RA, Walker LE. Antigens associated with a human lung adenocarcinoma defined by monoclonal antibodies. Cancer Res. 1984; 44(2):681-687. (Immunogen: Immunofluorescence, Immunohistochemistry, Immunoprecipitation). View Reference
-
Varki NM, Reisfeld RA, Walker LE. Effect of monoclonal antibody-drug conjugates in teh in vivody growth of h uman tumors established in nude mice. In: Reisfeld R, Sell S, ed. Monoclonal Antibodies in Cancer Therapy, vol. 27. New York: Alan R Liss, Inc; 195:207.
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.